BioAtla (BCAB) Interest & Investment Income (2020 - 2026)
BioAtla's (BCAB) quarterly Interest & Investment Income came in at $16000.0 in Q2 2026, down 93.13% on a YoY basis from $233000.0 in Q2 2025, and down 56.76% quarter-over-quarter from $37000.0 in Q1 2026.
Powered by 
Analysis
BioAtla (BCAB) Interest & Investment Income (2020 - 2026) Analysis & Trends
BioAtla (BCAB) has reported Interest & Investment Income for 7 consecutive years, with $16000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Interest & Investment Income fell 93.13% year-over-year to $16000.0; the trailing twelve-month figure through Jun 2026 stood at $259000.0 (down 86.22% YoY), and the FY2025 full-year result was $843000.0, down 74.98% from the prior year.
- Interest & Investment Income declined to $16000.0 in Q2 2026 per BCAB's latest filing, from $37000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $1.7 million in Q3 2023 and bottomed at $16000.0 in Q2 2026.
- Historically, Interest & Investment Income has averaged $678944.4 across 5 years, with a median of $477000.0 in 2024.
- The sharpest annual moves came in 2023 and 2026: Interest & Investment Income surged 1641.18% in 2023, then sank 93.13% in 2026.
- Over 5 years, Interest & Investment Income stood at $1.0 million in 2022, then soared by 56.45% to $1.6 million in 2023, then sank by 66.18% to $554000.0 in 2024, then sank by 86.82% to $73000.0 in 2025, then slumped by 78.08% to $16000.0 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $16000.0, $37000.0, and $73000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 120.60 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | -48.00 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 48.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 67.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 36.92 Mn |
| 10 | BioAtla | 2.33 Mn | 2.33 Mn | - | 16,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 16,000.00 |
| Mar 31, 2026 | 37,000.00 |
| Dec 31, 2025 | 73,000.00 |
| Sep 30, 2025 | 133,000.00 |
| Jun 30, 2025 | 233,000.00 |
| Mar 31, 2025 | 400,000.00 |
| Dec 31, 2024 | 554,000.00 |
| Sep 30, 2024 | 692,000.00 |
| Jun 30, 2024 | 900,000.00 |
| Mar 31, 2024 | 1.22 Mn |
| Dec 31, 2023 | 1.64 Mn |
| Sep 30, 2023 | 1.73 Mn |
| Jun 30, 2023 | 1.46 Mn |
| Mar 31, 2023 | 1.48 Mn |
| Dec 31, 2022 | 1.05 Mn |
| Sep 30, 2022 | 370,000.00 |
| Jun 30, 2022 | 146,000.00 |
| Mar 31, 2022 | 85,000.00 |
| Dec 31, 2021 | 96,000.00 |
| Sep 30, 2021 | 76,000.00 |